Ventraburn 7

VENTRABURN 7 is a potent thermogenic blend combining Yohimbine HCl and Albuterol, formulated to enhance fat loss, metabolic rate, and adrenal drive.

From AED 250.00

format:

Key Ingredients

Yohimbine HCI, Albuterol

Fat Burning Support

Fat Metabolism Support

Increases Endurance

Not sure about the right dosage?

Use our Peptide Dosage Calculator for optimal application

Main Information

VENTRABURN 7 is a dual-action fat loss accelerator that combines two powerful adrenergic agents:

• Yohimbine HCl – An alpha-2 adrenergic antagonist that increases norepinephrine release, enhances lipolysis, and targets stubborn fat stores (especially in fasted states).

• Albuterol – A selective beta-2 agonist that stimulates thermogenesis, bronchodilation, and increases energy expenditure without affecting estrogen or testosterone levels.

Scientific Background

Ventraburn 7 is a potent injectable fat-loss formulation combining Yohimbine, a selective α2-adrenergic antagonist, with Albuterol, a β2-adrenergic receptor agonist. This synergistic blend is engineered to break through stubborn fat plateaus by enhancing lipolysis, improving blood flow to resistant fat areas, and amplifying catecholamine-driven fat release—especially under fasted or adrenergically primed conditions.Yohimbine blocks α2 receptors in adipose tissue, which normally inhibit fat breakdown. This “removes the brakes” on lipolysis, making it particularly effective in hard-to-burn areas like the lower abdomen, flanks, and thighs. Albuterol, a β2 agonist, increases intracellular cAMP, triggering hormone-sensitive lipase activation and the mobilization of fatty acids for mitochondrial oxidation [1][2]. Unlike oral stimulants, injectable delivery ensures rapid absorption and localized activity, minimizing systemic overstimulation while maximizing targeted fat mobilization.

What Makes Ventraburn 7 Unique

Combines α2 antagonism (Yohimbine) and β2 stimulation (Albuterol) for dual-pathway lipolysis activation
Specifically formulated for fasted cardio, cutting phases, and body contouring protocols
Supports localized fat access where adrenergic resistance is typically high
Can be used in microdosing protocols to minimize stimulant load while maximizing outcome
Enhances energy availability, vascular definition, and physique refinement without hormonal interference

Ideal for experienced users looking to accelerate stubborn fat loss, break through metabolic plateaus, or fine-tune conditioning during peak phases.

References

Galitzky J et al. Alpha2-adrenergic antagonists and lipolysis in human fat cells. J Clin Invest. 1993;91(2):790–795. doi: 10.1172/JCI116273
Lafontan M, Berlan M. Fat cell adrenergic receptors and the control of white and brown fat cell function. J Lipid Res. 1993;34(7):1057–1091.

Usage Instructions

Ventraburn 7 is an advanced injectable fat-loss solution intended for subcutaneous use, especially in stubborn fat areas. It combines Yohimbine and Albuterol to target adrenergically resistant fat cells and promote enhanced lipolysis during fasted or high-output states.

Administration route: Subcutaneous injection (e.g., lower abdomen, flanks, thighs)
Needle size: 29–31G insulin syringe
Injection timing: Ideally 20–40 minutes before fasted cardio, HIIT, or cutting-phase trainingStorage: Refrigerate between 2–8 °C; protect from light
Cycle duration: Typically used in 4–6 week cycles with breaks in between

Dosage Information

Fat Loss Acceleration / Fasted Cardio Protocol

0.3–0.5 mL, injected once daily, preferably AM before cardio
Start with lower dose to assess tolerance and titrate upward after 3–5 days

Targeted Body Recomposition / Cutting Phase

0.5 mL, injected 5× per week, focused on resistant areas

Best combined with caloric deficit and stimulant-free fat-loss support (e.g., L-Carnitine)

Advanced Prep / Competition Protocol

0.5–0.75 mL daily, for up to 3 consecutive weeks, followed by a 2-week off-phase

Combine with GH secretagogues or thyroid modulation if clinically supervised

Always inject away from major blood vessels and rotate sites to minimize irritation.

Important Warnings

Do not use in individuals with cardiovascular disease, high blood pressure, arrhythmias, or anxiety disorders
Not recommended for those with hyperthyroidism, glaucoma, or seizure disorders
May cause restlessness, tachycardia, tremors, or lightheadedness, especially at higher doses
Avoid combining with other stimulants, high-dose caffeine, or MAO inhibitors
Not for use during pregnancy or breastfeeding
Individuals with renal or hepatic impairment should consult a healthcare provider before use
Discontinue immediately if experiencing chest pain, severe agitation, or persistent palpitations
Use only as part of a structured protocol under professional guidance; not for continuous long-term use
Keep out of reach of children. For research or advanced performance support only.